Verve Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Verve Therapeutics reports increased collaboration revenue and provides updates on its clinical programs in its Q1 2025 financial results.
10-Q: Verve Therapeutics Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update
Verve Therapeutics reports a net loss of $50.1 million for the third quarter of 2024, while advancing its clinical programs for gene editing therapies.
Verve Therapeutics reports a net loss of $98.5 million for the first half of 2024, while advancing its gene editing programs and initiating a Phase 1b clinical trial for VERVE-102.
10-Q: Verve Therapeutics Reports First Quarter 2024 Financial Results and Provides Clinical Program Update
Verve Therapeutics reports a net loss of $48.7 million for the first quarter of 2024, while advancing its gene editing programs and pausing enrollment in the Heart-1 trial.